Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a

References

• Lin YH, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL, Lee DF. Osteosarcoma: molecular pathogenesis and iPSC modeling. Trends Mol Med. 2017;23:737–755. doi:10.1016/j.molmed.2017.06.004.
   PubMed Web of Science ®Google Scholar
• Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–3035. doi:10.1200/jco.2014.59.4895.
   PubMed Web of Science ®Google Scholar
• Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017;13:480–491. doi:10.1038/nrendo.2017.16.
   PubMed Web of Science ®Google Scholar
• Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14:722–735. doi:10.1038/nrc3838.
   PubMed Web of Science ®Google Scholar
• Zanotti S, Canalis E. Notch signaling and the skeleton. Endocr Rev. 2016;37:223–253. doi:10.1210/er.2016-1002.
   PubMed Web of Science ®Google Scholar
• Wagner ER, Luther G, Zhu G, Luo Q, Shi Q, Kim SH, Gao JL, Huang E, Gao Y, Yang K, et al. Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma. 2011;2011:325238. doi:10.1155/2011/325238.
   PubMedGoogle Scholar
• Yang Z, Li X, Yang Y, He Z, Qu X, Zhang Y. Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell Death Dis. 2016;7:e2389. doi:10.1038/cddis.2016.272.
   PubMed Web of Science ®Google Scholar
• Li Z, Dou P, Liu T, He S. Application of long noncoding RNAs in osteosarcoma: biomarkers and therapeutic targets. Cell Physiol Biochem. 2017;42:1407–1419. doi:10.1159/000479205.
   PubMed Web of Science ®Google Scholar
• Zhao J, Ma ST. Downregulation of lncRNA H19 inhibits migration and invasion of human osteosarcoma through the NF-kappaB pathway. Mol Med Rep. 2018;17:7388–7394. doi:10.3892/mmr.2018.8746.
   PubMed Web of Science ®Google Scholar
• Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol. 2015;36:1477–1486. doi:10.1007/s13277-014-2631-4.
   PubMed Web of Science ®Google Scholar
• Tian ZZ, Guo XJ, Zhao YM, Fang Y. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. Int J Clin Exp Pathol. 2015;8:15138–15142.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang L, Hu X, Jiang Y, Hu Y, Liu Z, Liu J, Wen T, Ma Y, An G, et al. Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo. Oncotarget. 2017;8:3441–3453. doi:10.18632/oncotarget.13840.
   PubMedGoogle Scholar
• Lu YB, Jiang Q, Yang MY, Zhou JX, Zhang Q. Long noncoding RNA NNT-AS1 promotes hepatocellular carcinoma progression and metastasis through miR-363/CDK6 axis. Oncotarget. 2017;8:88804–88814. doi:10.18632/oncotarget.21321.
   PubMedGoogle Scholar
• Hua F, Liu S, Zhu L, Ma N, Jiang S, Yang J. Highly expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/beta-catenin signaling pathway in cervical cancer. Biomed Pharmacother. 2017;92:1128–1134. doi:10.1016/j.biopha.2017.03.057.
   PubMed Web of Science ®Google Scholar
• Lv G, Wu M, Wang M, Jiang X, Du J, Zhang K, Li D, Ma N, Peng Y, Wang L, et al. miR-320a regulates high mobility group box 1 expression and inhibits invasion and metastasis in hepatocellular carcinoma. Liver Int. 2017;37:1354–1364. doi:10.1111/liv.13424.
   PubMed Web of Science ®Google Scholar
• Lv Q, Jx H, Yj L, Xie N, Song DD, Zhao W, Yan YF, Bs L, Wang PY, Xie SY. MiR-320a effectively suppresses lung adenocarcinoma cell proliferation and metastasis by regulating STAT3 signals. Cancer Biol Ther. 2017;18:142–151. doi:10.1080/15384047.2017.1281497.
   PubMed Web of Science ®Google Scholar
• Yu J, Wang JG, Zhang L, Yang HP, Wang L, Ding D, Chen Q, Yang WL, Ren KH, Zhou DM, et al. MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin. Oncotarget. 2016;7:38612–38625. doi:10.18632/oncotarget.9572.
   PubMedGoogle Scholar
• Wang W, Zhao L, Wei X, Wang L, Liu S, Yang Y, Wang F, Sun G, Zhang J, Ma Y, et al. MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells. Sci Rep. 2016;6:27641. doi:10.1038/srep27641.
   PubMed Web of Science ®Google Scholar
• Hamam D, Ali D, Vishnubalaji R, Hamam R, Al-Nbaheen M, Chen L, Kassem M, Aldahmash A, Alajez NM. microRNA-320/RUNX2 axis regulates adipocytic differentiation of human mesenchymal (skeletal) stem cells. Cell Death Dis. 2014;5:e1499. doi:10.1038/cddis.2014.462.
   PubMed Web of Science ®Google Scholar
• Sun JY, Huang Y, Li JP, Zhang X, Wang L, Meng YL, Yan B, Bian YQ, Zhao J, Wang WZ, et al. MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin. Biochem Biophys Res Commun. 2012;420:787–792. doi:10.1016/j.bbrc.2012.03.075.
   PubMed Web of Science ®Google Scholar
• Wang J, Shi C, Wang J, Cao L, Zhong L, Wang D. MicroRNA-320a is downregulated in non-small cell lung cancer and suppresses tumor cell growth and invasion by directly targeting insulin-like growth factor 1 receptor. Oncol Lett. 2017;13:3247–3252. doi:10.3892/ol.2017.5863.
   PubMed Web of Science ®Google Scholar
• Guo T, Feng Y, Liu Q, Yang X, Jiang T, Chen Y, Zhang Q. MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R. Tumour Biol. 2014;35:11269–11275. doi:10.1007/s13277-014-2283-4.
   PubMedGoogle Scholar
• Wang W, Li X, Meng FB, Wang ZX, Zhao RT, Yang CY. Effects of the long non-coding RNA HOST2 on the proliferation, migration, invasion and apoptosis of human osteosarcoma cells. Cell Physiol Biochem. 2017;43:320–330. doi:10.1159/000480412.
   PubMed Web of Science ®Google Scholar
• Rodriguez LG, Wu X, Guan JL. Wound-healing assay. Methods Mol Biol. 2005;294:23–29.
   PubMedGoogle Scholar
• Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3:1113–1121. doi:10.1158/2159-8290.cd-13-0202.
   PubMed Web of Science ®Google Scholar
• Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA Interactions. Methods Mol Biol. 2016;1402:271–286. doi:10.1007/978-1-4939-3378-5_21.
   PubMedGoogle Scholar
• Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P, Floros E, Dalamagas T, et al. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016;44:D231–8. doi:10.1093/nar/gkv1270.
   PubMed Web of Science ®Google Scholar
• Zhang CL, Wang H, Yan CY, Gao XF, Ling XJ. Deregulation of RUNX2 by miR-320a deficiency impairs steroidogenesis in cumulus granulosa cells from polycystic ovary syndrome (PCOS) patients. Biochem Biophys Res Commun. 2017;482:1469–1476. doi:10.1016/j.bbrc.2016.12.059.
   PubMed Web of Science ®Google Scholar
• Xie Y, Sun W, Deng Z, Zhu X, Hu C, Cai L. MiR-302b suppresses osteosarcoma cell migration and invasion by targeting Runx2. Sci Rep. 2017;7:13388. doi:10.1038/s41598-017-13353-9.
   PubMed Web of Science ®Google Scholar
• He Y, Meng C, Shao Z, Wang H, Yang S. MiR-23a functions as a tumor suppressor in osteosarcoma. Cell Physiol Biochem. 2014;34:1485–1496. doi:10.1159/000366353.
   PubMed Web of Science ®Google Scholar
• Chiu YJ, Hour MJ, Jin YA, Lu CC, Tsai FJ, Chen TL, Ma H, Juan YN, Yang JS. Disruption of IGF1R signaling by a novel quinazoline derivative, HMJ30, inhibits invasiveness and reverses epithelial-mesenchymal transition in osteosarcoma U2 OS cells. Int J Oncol. 2018. doi:10.3892/ijo.2018.4325.
   Web of Science ®Google Scholar
• Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CG. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017;18:895–903. doi:10.1080/15384047.2017.1345397.
   PubMed Web of Science ®Google Scholar
• Ye H, Lin J, Yao X, Li Y, Lin X, Lu H. Overexpression of long non-coding RNA NNT-AS1 correlates with tumor progression and poor prognosis in osteosarcoma. Cell Physiol Biochem. 2018;45:1904–1914. doi:10.1159/000487966.
   PubMed Web of Science ®Google Scholar
• Cohen-Solal KA, Boregowda RK, Lasfar A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015;14:137. doi:10.1186/s12943-015-0404-3.
   PubMed Web of Science ®Google Scholar
• Lv GY, Miao J, Zhang XL. Long non-coding RNA XIST promotes osteosarcoma progression by targeting ras-related protein RAP2B via miR-320b. Oncol Res. 2017. doi:10.3727/096504017X14920318811721.
   Web of Science ®Google Scholar
• Wu H, Li W, Zhang M, Zhu S, Zhang D, Wang X. Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1. J Cancer Res Ther. 2016;12:68–71. doi:10.4103/0973-1482.191635.
   PubMed Web of Science ®Google Scholar
• Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Orntoft TF, Andersen CL, Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008;68:10094–10104. doi:10.1158/0008-5472.CAN-08-1569.
   PubMed Web of Science ®Google Scholar
• Vishnubalaji R, Hamam R, Yue S, Al-Obeed O, Kassem M, Liu FF, Aldahmash A, Alajez NM. MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1. Oncotarget. 2016;7:35789–35802. doi:10.18632/oncotarget.8937.
   PubMedGoogle Scholar
• Zhang T, Zou P, Wang T, Xiang J, Cheng J, Chen D, Zhou J. Down-regulation of miR-320 associated with cancer progression and cell apoptosis via targeting Mcl-1 in cervical cancer. Tumour Biol. 2016;37:8931–8940. doi:10.1007/s13277-015-4771-6.
   PubMedGoogle Scholar
• Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, Yeh SD, Hong TM, Chen YL. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 2013;34:530–538. doi:10.1093/carcin/bgs371.
   PubMed Web of Science ®Google Scholar
• Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: accelerating progress makes for a hopeful future. Front Oncol. 2018;8:4. doi:10.3389/fonc.2018.00004.
   PubMed Web of Science ®Google Scholar